Medical Devices / MedTech: Business Valuation & Sale Guide

How Medical Devices / MedTech Companies Are Valued

Smaller device manufacturers are typically assessed on SDE, while businesses with a quality-system and regulatory-affairs function are more naturally evaluated on normalized EBITDA. A buyer reviews FDA regulatory pathway and clearance status (510(k), De Novo, or PMA), patent and IP protection, quality-system compliance (ISO 13485/QSR) history, and customer concentration among hospital systems, distributors, or group purchasing organizations.

OwnerGauge applies a reviewed medical-devices-specific multiple range to the assessment, informed by public 2025-2026 benchmark data — the category is manufacturing-adjacent but carries an IP and regulatory-moat premium over general specialty manufacturing, provided clearance status and quality-system compliance hold up under diligence.

The assessment applies a reviewed multiple range for this industry, informed by public benchmark data — it remains a directional planning estimate, not a transaction comp. See our methodology →

Revenue Quality in Medical Devices / MedTech

• —A cleared or approved device with supporting clinical evidence carries real, durable economic value beyond the underlying technology — buyers price the regulatory moat, not just the product.
• —Revenue tied to reimbursed procedures with established CPT codes is more durable than revenue dependent on off-label use or uncertain reimbursement.
• —Distributor or GPO-driven revenue can bring volume but often at thinner margin and with less direct customer-relationship control than direct sales.

Owner Dependency

• —The founder is often the person who holds the core regulatory and clinical relationships, and may be the named inventor on key patents.
• —A buyer tests whether regulatory affairs, quality systems, and key clinical relationships extend beyond the founder.

Management & Workforce

• —Regulatory affairs and quality-system expertise is specialized and scarce, and a lapse in quality-system compliance can jeopardize clearance status itself.
• —Buyers look for a documented quality-management system, regulatory-affairs leadership, and manufacturing/supply-chain redundancy beyond the founder.

What Can Make the Business More Attractive

• —Expand or strengthen patent and IP protection around the core product
• —Pursue additional indications or reimbursement codes to broaden addressable use
• —Document quality-system compliance and resolve any audit findings
• —Diversify customer concentration among hospital systems, distributors, and GPOs

What Can Influence Valuation

• —FDA regulatory pathway and clearance/approval status
• —Patent and intellectual-property protection
• —Quality-system compliance history (ISO 13485/QSR) and any audit findings
• —Reimbursement and CPT-code coverage supporting adoption
• —Customer concentration among hospital systems, distributors, or GPOs

What Buyers May Evaluate

• —Regulatory pathway, clearance status, and any pending submissions
• —Patent protection, freedom-to-operate, and IP litigation history
• —Quality-system audit history and any FDA warning letters or 483 observations
• —Reimbursement coverage and customer/distributor concentration

Common Transaction Risks

• —Clearance or approval status is narrower than the sales pipeline assumes
• —Patent protection is weak, expiring soon, or contested
• —Open FDA warning letters, 483 observations, or unresolved quality-system findings
• —Revenue is concentrated in a small number of distributors, GPOs, or hospital systems

Preparing the Company for Sale

• —Confirm and document regulatory clearance/approval status and any pending submissions
• —Review patent protection and freedom-to-operate before going to market
• —Resolve any open quality-system or FDA compliance findings
• —Diversify customer and distributor concentration where feasible

How the Sale Process Works

Every sale moves through the same general stages — preparation, valuation, positioning, marketing, buyer outreach, indications of interest, a letter of intent, due diligence, definitive documentation, and closing.